Hib meningococcal group C vaccine (GlaxoSmithKline)

Hib-C型脑膜炎球菌疫苗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHib meningococcal group C vaccine (GlaxoSmithKline)
Drug Alias NameMeningococcal groups C and Haemophilus influenzae type-b vaccineHib-MenC-TT conjugated vaccineHib-MenC conjugated vaccineHib-MenC vaccineHib-MenC +[7] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccineVaccines > Biological material > Bacterial vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHaemophilus InfectionsMeningitis, Meningococcal
Global Approved IndicationsHaemophilus InfectionsMeningitis, Meningococcal
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2005/12/01
Country/TerritoryAustraliaUnited Kingdom
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsHaemophilus InfectionsMeningitis, Meningococcal
Inactive IndicationsN/A

Other Information

ATC CodeJ07AG53
Related LinksN/A